Harmony Biosciences
(NASDAQ) HRMY
Harmony Biosciences Financials at a Glance
Market Cap
$2.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$899.11M
Net Income (TTM)
$145.62M
EPS (TTM)
$2.48
P/E Ratio
15.39
Dividend
$0.00
Beta (Volatility)
0.83 (Low)
Dividend
$0.00
Beta (Volatility)
0.83 (Low)
Price
$36.76
Volume
668,823.369
Open
$38.44
Price
$36.76
Volume
668,823.369
Open
$38.44
Previous Close
$36.84
Daily Range
$36.17 - $38.50
52-Week Range
$25.52 - $40.87
Estimated Earnings Date
Aug 4, 2026
Dividend
$0.00
Beta (Volatility)
0.83 (Low)
Price
$36.76
Volume
668,823.369
Open
$38.44
Previous Close
$36.84
Daily Range
$36.17 - $38.50
52-Week Range
$25.52 - $40.87
Estimated Earnings Date
Aug 4, 2026
HRMY News
HRMY: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Harmony Biosciences
Industry
Pharmaceuticals
Sector
Health CareEmployees
293
CEO
Jeffrey M. Dayno, MD
Website
www.harmonybiosciences.comHeadquarters
Plymouth Meeting, PA 19462, US
HRMY Financials
Key Financial Metrics (TTM)
Gross Margin
76.55%
Operating Margin
21.08%
Net Income Margin
16.20%
Return on Equity
17.19%
Return on Capital
18.78%
Return on Assets
11.45%
Earnings Yield
6.50%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$2.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
57.89M
Volume
668.82K
Avg. Volume
841.76K
Financials (TTM)
Gross Profit
$688.25M
Operating Income
$189.51M
EBITDA
$233.34M
Operating Cash Flow
$341.97M
Capital Expenditure
-$182.00K
Free Cash Flow
$341.79M
Cash & ST Invst.
$640.92M
Total Debt
$206.52M
Harmony Biosciences Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$215.39M
+16.6%
Gross Profit
$170.88M
+11.9%
Gross Margin
79.33%
N/A
Market Cap
$2.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$8.25M
N/A
Employees
268
N/A
Net Income
$32.49M
-28.7%
EBITDA
$48.89M
-27.0%
Quarterly Fundamentals
Total Cash
$640.92M
+26.4%
Total Debt
$206.52M
+16.4%
Accounts Receivable
$108.22M
+2.1%
Inventory
$5.28M
-17.3%
Long Term Debt
$143.34M
-9.7%
Short Term Debt
$63.17M
+238.8%
Return on Assets
11.45%
N/A
Return on Invested Capital
17.97%
N/A
Free Cash Flow
$27.76M
-18.0%
Operating Cash Flow
$27.76M
-18.3%